Clinical Trial

A Study of BR111 in Patients With Advanced Malignancies

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase I, multicenter, open-label, single-arm and first-in-human clinical study of BR111-101 for injection. The study objectives are to evaluate the safety, tolerability, pharmacokinetic profile, anti-tumor activity and immunogenicity of BR111-101 for injection in patients with advanced malignancies.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-14; most recent amendment 2025-11-18.
Status change: Not Yet Recruiting → Recruiting 2025-11-18
Trial Details
NCT Number NCT06937957
Lead Sponsor BioRay Pharmaceutical Co., Ltd.
Conditions Advanced Malignancies
Enrollment 166 participants
Start Date 2025-04-24
Primary Completion 2027-10-09 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-11-21